SEARCH

SEARCH BY CITATION

References

  • 1
    Johnson PW, Rohatiner AZ, Whelan JS, et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol 1995;13:1407.
  • 2
    GLOBOCAN. 2002 database. Available from: http://www-dep.iarc.fr/GLOBOCAN_frame.htm[Accessed May 19, 2008.
  • 3
    Cancer Research UK. UK Non-Hodgkin lymphoma incidence statistics. Available from: http://info.cancerresearchuk.org/cancerstats/types/nhl/incidence/#source8[Accessed December 4, 2008.
  • 4
    Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998;16:278095.
  • 5
    Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004;104:125865.
  • 6
    National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology—version 1. 2005: non-Hodgkin's Lymphoma. Available from: http://www.nccn.org[Accessed April 4, 2008.
  • 7
    Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 1984;311:14715.
  • 8
    Ardeshna KM, Smith P, Norton A, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomized controlled trial. Lancet 2003;62:51622.
  • 9
    Wake BL, Bryan S, Barton P, et al. Rituximab as Third-Line Treatment of Refractory or Recurrent Stage III or IV Follicular Non-Hodgkin's Lymphoma. Birmingham: University of Birmingham, Department of Public Health and Epidemiology, 2001.
  • 10
    European Medicines Agency (EMEA). Mabthera Summary of Product Characteristics (2008). Available from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/Mabthera/emea-combined-h165en.pdf[Accessed December 4, 2008.
  • 11
    Herold M, Haas A, Srock S, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 2007;25:198692.
  • 12
    Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008;26:457986.
  • 13
    Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) significantly improves the outcomes for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Study Group. Blood 2005;106:372532.
  • 14
    Foussard C, Mounier N, Van Hoof A, et al. Update of the FL 2000 randomized trial combining rituximab to CHVP-interferon in follicular lymphoma patients. J Clin Oncol 2006;24(Suppl. 18):S7508.
  • 15
    National Institute for Health and Clinical Excellence. Guide to the Methods of Technology Appraisal. London: NICE, 2004.
  • 16
    Horning SJ. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Sem in Oncol 1993;20:7588.
  • 17
    Scottish Medicines Consortium, NHS Scotland. Rituximab: New Product Assessment. Available from: http://www.scottishmedicines.org.uk/smc/files/Microsoft%20Word%20%20rituximab%20MabThera%20FINAL%20May%202009.pdf, 2007 [Accessed November 26, 2009.
  • 18
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. JASA 1958;53:45781.
  • 19
    Pettengell R, Donatti C, Hoskin P, et al. The impact of follicular lymphoma on health-related quality of life. Ann Oncol 2008;19:5706.
  • 20
    Briggs A, Sculpher M, Cloaxton K. Decision Modelling for Economic Evaluation. Oxford: Oxford University Press, 2006.
  • 21
    Office for National Statistics. Statistical Bulletin Consumer Price Indices. Available from: http://www.statistics.gov.uk/pdfdir/cpi0109, 2009 [Accessed February 2, 2009.
  • 22
    Edelman MJ, Meyers FJ, Siegel D. The utility of follow-up testing after curative cancer therapy. A critical review and economic analysis. J Gen Intern Med 1997;12:31831.
  • 23
    Tolley K, Morgan G, Cartwright R, Williams R. Economic Aspects of Non-Hodgkin's Lymphoma. London, UK: Office of Health Economics, 1998.
  • 24
    UK Department of Health. National Health Service Reference Costs (2006/07). London: Department of Health. Available from: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_082571[Accessed February 2, 2009.
  • 25
    Collett D. Modelling Survival Data in Medical Research (2nd ed.). Boca Raton, FL: Chapman & Hall/CRC, 2003.
  • 26
    Scotland and Newcastle Lymphoma Group. SNLG@ed.ac.uk: Database analysis (Roche data on file) 2004.
  • 27
    Wilmoth JR, Shkolnikov V. The human mortality database. Available from: http://www.mortality.org[Accessed April 18, 2008.
  • 28
    Tudor C, Williamson PR. The value of aggregate data approach in meta-analysis with time-to-event outcomes. J R Stat Soc A 2001;164(Part 2):35770.
  • 29
    MIMS. Monthly index of medical specialties. Available from: http://www.healthcarerepublic.com/mims[Accessed April 10, 2007.
  • 30
    National Institute for Clinical Excellence. Technology appraisal 110. Rituximab for the treatment of follicular lymphoma. September 2006. Available from: http://www.nice.org.uk/guidance/TA110[Accessed February 2, 2009.
  • 31
    Knight C, Hind D, Brewer N, Abbott V. Rituximab for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation. Health Technol Assess 2004;8:1ix, 1–82.
  • 32
    Drummond MF, O’Brien B, Stoddart GL, et al. Methods for Economic Evaluation of Health Care Programmes. Oxford: Oxford University Press, 2003.
  • 33
    Philips Z, Bojke L, Sculpher M, et al. Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment. Pharmacoeconomics 2006;24:35571.
  • 34
    Birch S, Gafni A. Changing the problem to fit the solution: Johannesson and Weisteins (mis)application of economics to real world problems. J Health Econ 1193:46976.
  • 35
    Hornberger J, Reyes C, Lubeck D, Valente N. Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma. Leuk Lymphoma 2008;49:22736.
  • 36
    Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105:141723.
  • 37
    Geary U, Lewis G, Aultman R, Arirstides M. A cost-utility of maintenance rituximab for the treatment of relapsed/refractory follicular non-lymphoma (NHL) in the UK. ISPOR 10th Annual European Congress October 20–23, 2007, Dublin, Ireland. Abstract PCN46.
  • 38
    Kasteng F, Erlanson M, Hagberg H, et al. Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden. Acta Oncol 2008;47:102936.
  • 39
    Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York: John Wiley & Sons, Inc., 1980.
  • 40
    Gibben JG. How I treat lymphoma. Blood 2007;109:461726.
  • 41
    Van Agthoven M, Sonneveld P, Verdonck L, et al. Cost determinants in agressive non-Hodgkin's lymphoma. Haematologica 2005;90:66171.
  • 42
    Sutton A, Ades AE, Cooper N, Abrams K. Use of indirect and mixed treatment comparisons for technology assessment. Pharmacoeconomics 2008;26:75367.